Catalog No.
DHF86301
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
IL-5R subunit alpha, IL-5 receptor subunit alpha, IL5RA, IL-5RA, IL-5R-alpha, Interleukin-5 receptor subunit alpha, CDw125, CD125, IL5R
Concentration
1.17 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q01344
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
BIW-8405, KHK4563, MEDI-563, CAS: 1044511-01-4
Clone ID
Benralizumab
Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma, PMID: 28530840
Benralizumab for the Prevention of COPD Exacerbations, PMID: 31112385
Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma, PMID: 32034960
Real-World Effectiveness of Benralizumab in Severe Eosinophilic Asthma, PMID: 32882249
Benralizumab for PDGFRA-Negative Hypereosinophilic Syndrome, PMID: 30943337
Benralizumab for asthma, PMID: 30410214
Benralizumab: an updated treatment of eosinophilic asthma, PMID: 32133878
Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β 2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial, PMID: 27609408
Benralizumab for Chronic Spontaneous Urticaria, PMID: 32997916
Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial, PMID: 27609406
Benralizumab: A New Approach for the Treatment of Severe Eosinophilic Asthma, PMID: 31017107
Asthma exacerbations on benralizumab are largely non-eosinophilic, PMID: 32767484
Benralizumab as a Steroid-Sparing Treatment Option in Eosinophilic Granulomatosis with Polyangiitis, PMID: 33065367
Benralizumab: First Global Approval, PMID: 29464664
Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial, PMID: 30416083
Benralizumab, PMID: 31643952
Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial, PMID: 33357499
Safety of Eosinophil-Depleting Therapy for Severe, Eosinophilic Asthma: Focus on Benralizumab, PMID: 32242310
Efficacy of benralizumab for patients with severe eosinophilic asthma: a retrospective, real-life study, PMID: 32746787
Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma, PMID: 32064642
Benralizumab, PMID: 30000011
Benralizumab after sub-optimal response to mepolizumab in severe eosinophilic asthma, PMID: 33300186
Benralizumab efficacy for patients with fixed airflow obstruction and severe, uncontrolled eosinophilic asthma, PMID: 31626906
Benralizumab for the treatment of asthma, PMID: 28379047
Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia, PMID: 23866823
Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma, PMID: 31836949
Benralizumab for the treatment of asthma, PMID: 29517082
Corticosteroid tapering with benralizumab treatment for eosinophilic asthma: PONENTE Trial, PMID: 31579676
Two-year integrated steroid-sparing analysis and safety of benralizumab for severe asthma, PMID: 31859541
Benralizumab in Real Life, PMID: 32573458
Blood Eosinophil Depletion with Mepolizumab, Benralizumab, and Prednisolone in Eosinophilic Asthma, PMID: 32584603
Matching-adjusted indirect comparison of benralizumab versus interleukin-5 inhibitors for the treatment of severe asthma: a systematic review, PMID: 30309978
Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma, PMID: 30139780
Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies, PMID: 28919200
Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab, PMID: 32401603
Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study, PMID: 25306557
Benralizumab: an anti-IL-5 receptor α monoclonal antibody in the treatment of asthma, PMID: 29359607
Benralizumab, an add-on treatment for severe eosinophilic asthma: evaluation of exacerbations, emergency department visits, lung function, and oral corticosteroid use, PMID: 30425502
Benralizumab as a potential treatment of asthma, PMID: 28406319
Efficacy and steroid-sparing effect of benralizumab: has it an advantage over its competitors?, PMID: 31024635
Modulation of blood inflammatory markers by benralizumab in patients with eosinophilic airway diseases, PMID: 30658649
The relationship between Feno and effectiveness of mepolizumab and benralizumab in severe eosinophilic asthma, PMID: 33486140
Benralizumab in the treatment of severe asthma: design, development and potential place in therapy, PMID: 29606855
Real-life experience with benralizumab during 6 months, PMID: 32600318
Benralizumab: From the Basic Mechanism of Action to the Potential Use in the Biological Therapy of Severe Eosinophilic Asthma, PMID: 29862274
Rapid effect of benralizumab for severe asthma with chronic rhinosinusitis with nasal polyps, PMID: 33039667
Benralizumab for the add-on maintenance treatment of patients with severe asthma aged 12 years and older with an eosinophilic phenotype, PMID: 29972739
Benralizumab as initial treatment for chronic eosinophilic pneumonia, PMID: 32807690
Benralizumab strongly reduces blood basophils in severe eosinophilic asthma, PMID: 32762056
Anti-IL5 therapies for asthma, PMID: 28933516
For research use only. Not for human or drug use.
